Notably, 1 patient with KIT exon 9 mutant GIST tumor (Y503_F504insAY mutation) had a 27% reduction in tumor burden after cycle 1 (Fig. 1), but withdrew from the trial by choice due to persistent GI symptoms before the follow-up evaluation. This evidence concerns the gene KIT and neoplasm.